Exploring Efficacy and Predictors of Response to Venetoclax and Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study
- 12 November 2026
- journal article
- Published by Wiley in International Journal of Cancer
Abstract
This retrospective study aimed to identify molecular predictors of treatment response and survival in 207 newly diagnosed acute myeloid leukemia (AML) patients treated with Venetoclax combined with hypomethylating agents (VEN‐HMAs). After one treatment course, the composite complete remission (CR/CRi) rate was 69.6% (144/207), with 70.5% (93/132) of responders achieving minimal residual disease (MRD) negativity. According to the 2017 ELN risk stratification, the CR/CRi rates in the favorable‐, intermediate‐, and high‐risk groups were 77.2%, 64.0%, and 66.6%, respectively. For treatment response, RUNX1‐RUNX1T1 , FLT3‐ITD , and TP53 mutations independently predicted unfavorable to VEN‐HMAs therapy. Multivariable analysis identified NRAS and PTPN11 mutations as independent adverse prognostic factors for overall survival, while achievement of CR/CRi after the first treatment course and receiving hematopoietic stem cell transplantation (HSCT) were favorable predictors. Based on molecular status, patients were stratified into three prognostic groups. The median OS was 9.5 months in the TP53 ‐mutant (low‐benefit) group and 21 months in the medium‐benefit group ( TP53 wild‐type with FLT3‐ITD or K / NRAS mutations). The high‐benefit group (wild‐type TP53 , no FLT3‐ITD , and wild‐type K / NRAS ) had a significantly superior OS (not reached) compared to the others ( p < 0.001), while OS between the medium‐ and low‐benefit groups was comparable ( p = 0.096). VEN‐HMAs therapy is associated with high response rates in this real‐world cohort, though treatment response varies substantially by molecular profile. A comprehensive understanding of these influencing factors and the development of refined risk stratification systems require further investigation.Funding Information
- Changzhou Institute of Technology (CJ20243020)
- Changzhou Institute of Technology (CMCB202422)
- Changzhou Institute of Technology (GN202506)
- Changzhou Institute of Technology (TC2022JCYL11)
This publication has 37 references indexed in Scilit:
- Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentAmerican Journal of Hematology, 2024
- Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLLeukemia, 2024
- Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survivalAmerican Journal of Hematology, 2023
- Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?Blood Reviews, 2022
- Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysisCancer, 2021
- FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activationSignal Transduction and Targeted Therapy, 2021
- Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapyAmerican Journal of Hematology, 2021
- Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable‐risk acute myeloid leukemiaAmerican Journal of Hematology, 2020
- Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemiaLeukemia, 2020
- Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experienceLeukemia Research, 2018